Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 2
1978 1
1979 1
1981 1
1982 3
1984 3
1985 2
1986 2
1987 1
1989 3
1990 1
1992 2
1996 1
1998 1
1999 3
2000 6
2002 3
2003 2
2005 4
2006 4
2007 2
2008 4
2009 4
2010 5
2011 4
2012 5
2013 4
2014 8
2015 8
2016 12
2017 10
2018 8
2019 7
2020 4
2021 6
2022 8
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Ridker PM, et al. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28845751 Free article. Clinical Trial.
METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1beta, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. Th …
METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1beta, involv …
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults.
NCD Risk Factor Collaboration (NCD-RisC). NCD Risk Factor Collaboration (NCD-RisC). Lancet. 2017 Dec 16;390(10113):2627-2642. doi: 10.1016/S0140-6736(17)32129-3. Epub 2017 Oct 10. Lancet. 2017. PMID: 29029897 Free PMC article.
FINDINGS: Regional change in age-standardised mean BMI in girls from 1975 to 2016 ranged from virtually no change (-0.01 kg/m(2) per decade; 95% credible interval -0.42 to 0.39, posterior probability [PP] of the observed decrease being a true decrease=0.5098) in eastern Eu …
FINDINGS: Regional change in age-standardised mean BMI in girls from 1975 to 2016 ranged from virtually no change (-0.01 kg/m(2) per …
Stillbirths: rates, risk factors, and acceleration towards 2030.
Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, Flenady V, Frøen JF, Qureshi ZU, Calderwood C, Shiekh S, Jassir FB, You D, McClure EM, Mathai M, Cousens S; Lancet Ending Preventable Stillbirths Series study group; Lancet Stillbirth Epidemiology investigator group. Lawn JE, et al. Lancet. 2016 Feb 6;387(10018):587-603. doi: 10.1016/S0140-6736(15)00837-5. Epub 2016 Jan 19. Lancet. 2016. PMID: 26794078 Review.
The Every Newborn Action Plan has the target of 12 or fewer stillbirths per 1000 births in every country by 2030. 94 mainly high-income countries and upper middle-income countries have already met this target, although with noticeable disparities. ...
The Every Newborn Action Plan has the target of 12 or fewer stillbirths per 1000 births in every country by 2030. 94 mainly high-inco …
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses.
Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Lancet Diabetes Endocrinol. 2021 Dec;9(12):837-846. doi: 10.1016/S2213-8587(21)00263-1. Epub 2021 Oct 28. Lancet Diabetes Endocrinol. 2021. PMID: 34717822 Free PMC article. Retracted. Retracted and republished.
However, for the participants with vitamin D deficiency (25[OH]D concentration <25 nmol/L), genetic analyses provided strong evidence for an inverse association with all-cause mortality (odds ratio [OR] per 10 nmol/L increase in genetically-predicted 25[OH]D concentrati …
However, for the participants with vitamin D deficiency (25[OH]D concentration <25 nmol/L), genetic analyses provided strong evidence for …
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses.
Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Lancet Diabetes Endocrinol. 2024 Jan;12(1):e2-e11. doi: 10.1016/S2213-8587(23)00287-5. Epub 2023 Dec 1. Lancet Diabetes Endocrinol. 2024. PMID: 38048800 Free PMC article.
In population-wide genetic analyses, there were no associations of genetically predicted 25(OH)D with coronary heart disease (odds ratio [OR] per 10 nmol/L higher genetically-predicted 25(OH)D concentration 0.98, 95% CI 0.95-1.01), stroke (1.01, [0.97-1.05]), or all-cause …
In population-wide genetic analyses, there were no associations of genetically predicted 25(OH)D with coronary heart disease (odds ratio [OR …
Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies - A systematic review and meta-analyses.
Wennerholm UB, Bergman L, Kuusela P, Ljungström E, Möller AC, Hongslo Vala C, Ekelund AC, Liljegren A, Petzold M, Sjögren P, Svensson M, Strandell A, Jacobsson B. Wennerholm UB, et al. Front Med (Lausanne). 2023 Feb 28;10:1111315. doi: 10.3389/fmed.2023.1111315. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36936217 Free PMC article. Review.
A Scoping Review of Safety and Health Interventions in the High-Risk Dairy Industry: Gaps in Evidence Point to Future Directions in Research.
Driscoll M, Dalton D, Jenkins P, Tinc P, Murphy D, Douphrate DI, Lundqvist P, Pate M, Lindahl C, Meyerhoff A, Scott E, Carrabba J, Hagevoort GR, Sorensen J. Driscoll M, et al. J Agromedicine. 2022 Jan;27(1):51-63. doi: 10.1080/1059924X.2020.1837703. Epub 2020 Nov 14. J Agromedicine. 2022. PMID: 33191879 Review.
The occupational injury rate of the dairy industry (6.6 per 100 full-time workers) is twice that of the national average across all industries (3.3 per 100 full-time workers). ...
The occupational injury rate of the dairy industry (6.6 per 100 full-time workers) is twice that of the national average across all i …
The role of circulating galectin-1 in type 2 diabetes and chronic kidney disease: evidence from cross-sectional, longitudinal and Mendelian randomisation analyses.
Drake I, Fryk E, Strindberg L, Lundqvist A, Rosengren AH, Groop L, Ahlqvist E, Borén J, Orho-Melander M, Jansson PA. Drake I, et al. Diabetologia. 2022 Jan;65(1):128-139. doi: 10.1007/s00125-021-05594-1. Epub 2021 Nov 7. Diabetologia. 2022. PMID: 34743218 Free PMC article.
However, galectin-1 was associated with increased risk of type 2 diabetes (per SD increase, HR 1.12; 95% CI 1.02, 1.24). Two-sample MR analyses could not ascertain a causal effect of galectin-1 on CKD (OR 0.92; 95% CI 0.82, 1.02) or type 2 diabetes (OR 1.05; 95% CI 0.98, 1 …
However, galectin-1 was associated with increased risk of type 2 diabetes (per SD increase, HR 1.12; 95% CI 1.02, 1.24). Two-sample M …
Immobilized-biomembrane affinity chromatography for binding studies of membrane proteins.
Gottschalk I, Lagerquist C, Zuo SS, Lundqvist A, Lundahl P. Gottschalk I, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 25;768(1):31-40. doi: 10.1016/s0378-4347(01)00483-2. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 11939556 Review.
Analyses of the human facilitative glucose transporter GLUT1 by use of the inhibitor cytochalasin B (radioactively labeled) and the competitive substrate D-glucose (non-labeled) showed that GLUT1 interconverted between two states, exhibiting one or two cytochalasin B-binding site …
Analyses of the human facilitative glucose transporter GLUT1 by use of the inhibitor cytochalasin B (radioactively labeled) and the competit …
137 results